Trial Profile
Phase II multi-center trial of Apatinib combined with EGFR-TKIs therapy in slow progress and T790M of advanced non-small cell lung cancer after treatment with first-generation EGFR-TKIs
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IRB-2017-163
- 01 Nov 2017 New trial record